Omari Mouhsine, Bendimya Mohammed, Jebrouni Fadoua, Karich Nassira, Al Jarroudi Ouissam, Brahmi Sami Aziz, Bennani Amal, Afqir Said
Medical Oncology, Mohammed VI University Hospital, Oujda, MAR.
Medical Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Cureus. 2025 Apr 28;17(4):e83143. doi: 10.7759/cureus.83143. eCollection 2025 Apr.
Chromophobe renal cell carcinoma is a rare entity with an excellent prognosis compared with clear renal cell carcinoma and is characterized by distinct molecular and genetic specificity. The presence of a sarcomatoid component is an uncommon phenomenon, which indicates a high risk of metastasis and a poor prognosis. We present the case of a 44-year-old patient with chromophobe renal cell carcinoma with a sarcomatoid component. Therapeutic management presents a significant challenge given the absence of standards of care for this rare entity. The current treatments are based on vascular endothelial growth factor tyrosine kinase inhibitors, mammalian target of rapamycin pathway inhibitors, and immune checkpoint inhibitors. Close monitoring based on clinical, biological, and radiological examinations is necessary for rapid and appropriate interventions. Moreover, this histological variant represents a major clinical challenge, not only because of its aggressive behavior but also due to the absence of specific clinical manifestations and its frequent incidental discovery at an advanced stage, further complicating early diagnosis and management.
嫌色细胞肾细胞癌是一种罕见的肿瘤,与透明细胞肾细胞癌相比预后良好,具有独特的分子和基因特异性。肉瘤样成分的存在是一种不常见的现象,提示转移风险高且预后不良。我们报告一例44岁患有伴肉瘤样成分的嫌色细胞肾细胞癌患者。鉴于这种罕见肿瘤缺乏标准治疗方案,治疗管理面临重大挑战。目前的治疗方法基于血管内皮生长因子酪氨酸激酶抑制剂、雷帕霉素靶蛋白通路抑制剂和免疫检查点抑制剂。基于临床、生物学和影像学检查的密切监测对于快速和适当的干预是必要的。此外,这种组织学变异代表了一个重大的临床挑战,不仅因其侵袭性,还因其缺乏特异性临床表现且常在晚期偶然发现,进一步使早期诊断和管理复杂化。